Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Osiris Stem Cell Therapy Approved in Canada

By Pharmaceutical Processing | May 18, 2012

NEW YORK (AP) — Osiris Therapeutics Inc. said Thursday that Canadian regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants.

The company said Health Canada approved Prochymal for use against graft vs. host disease, a condition in which transplanted bone marrow cells attack the body of the patient. Prochymal is approved for use in children who are not responding to steroid therapy. Osiris said about 80 percent of child who contract graft vs. host disease die.

Osiris is still running clinical trials of Prochymal to support full marketing approval, but the drug was granted a type of conditional approval because of the lack of effective treatments for graft vs. host disease. Osiris is required to run additional studies to confirm the treatment works.

Marketing of Prochymal has not been approved in the U.S., but patients can get the treatment under certain conditions. The Food and Drug Administration allows the use of Prochymal in treatment of both adults and children with graft vs. host disease after steroids have failed.

Osiris, based in Columbia, Md., was developing Prochymal and a second stem cell treatment, Chondrogen, as part of a partnership with Genzyme, a unit of French drugmaker Sanofi. But in February Sanofi said it discontinued late-stage testing of Prochymal. Osiris said it believes Sanofi has terminated the collaboration and that it should regain all rights to Prochymal. Osiris said Sanofi disagrees and the companies are discussing their status.

Prochymal is also being studied as a treatment for Crohn’s disease and other conditions.

Shares of Osiris Therapeutics dipped 5 cents to $5.26 on Thursday and climbed 74 cents, or 14.1 percent, to $6 in after-hours trading.

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE